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A comprehensive revision of the Global Burden of Disease (GBD) study is expected to be completed in 2012. This
study utilizes a broad range of improved methods for assessing burden, including closer attention to empirically
derived estimates of disability. The aim of this paper is to describe how GBD health states were derived for
schizophrenia and bipolar disorder. These will be used in deriving health state-specific disability estimates. A
literature review was first conducted to settle on a parsimonious set of health states for schizophrenia and bipolar
disorder. A second review was conducted to investigate the proportion of schizophrenia and bipolar disorder cases
experiencing these health states. These were pooled using a quality-effects model to estimate the overall
proportion of cases in each state. The two schizophrenia health states were acute (predominantly positive
symptoms) and residual (predominantly negative symptoms). The three bipolar disorder health states were
depressive, manic, and residual. Based on estimates from six studies, 63% (38%-82%) of schizophrenia cases were in
an acute state and 37% (18%-62%) were in a residual state. Another six studies were identified from which 23%
(10%-39%) of bipolar disorder cases were in a manic state, 27% (11%-47%) were in a depressive state, and 50%
(30%-70%) were in a residual state. This literature review revealed salient gaps in the literature that need to be
addressed in future research. The pooled estimates are indicative only and more data are required to generate
more definitive estimates. That said, rather than deriving burden estimates that fail to capture the changes in
disability within schizophrenia and bipolar disorder, the derived proportions and their wide uncertainty intervals will
be used in deriving disability estimates.
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Considerable progress has been made over the last
15 years in establishing the extent to which mental dis-
orders as a group and individual disorders contribute to
disease burden. The Global Burden of Disease (GBD)
study has been influential in quantifying these contribu-
tions [1]. The first GBD study used disability-adjusted
life years (DALYs) to provide gender- and age-specific
burden estimates for over 100 diseases, injuries, and risk* Correspondence: alize_ferrari@qcmhr.uq.edu.au
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reproduction in any medium, provided the orfactors in eight regions of the world in the year 1990 [2].
Such estimates of burden have been used in a range of
public health contexts such as the prioritization of gov-
ernmental funding in health service delivery and re-
search [3-6]. Refinement of the DALY methodology, for
example the derivation of social preferences such as the
disability weights, as well as the epidemiological data
used in DALY calculations, is necessary to ensure that
burden estimates are as accurate as possible [7].
While the World Health Organization (WHO) has
provided interim updates of GBD estimates since 2000
for the world and 14 regions, a new GBD study (GBD
2010 Study) is expected to be completed by 2012 [8].
The GBD 2010 Study utilizes improved methods for
assessing burden [3] and will provide estimates oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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concerns the nonfatal component of DALYs, i.e., the
years of life lived with a disability (YLD). There has been
much debate surrounding the manner in which disability
is operationalized [9]. The literature on summary mea-
sures of population health uses the concept of “health
states” in their definition of disability. Disability is under-
stood in terms of individuals with a disorder spending
time in one or more health states associated with that
disorder [9].
What constitutes a health state and how it should be
measured will depend on the summary measure being
used and its function [9]. For GBD purposes, a principle
of “treating like health outcomes as like” is assumed
when defining health states. This contends that a par-
ticular disease will result in health states with the same
level of disability across multiple settings [10]. Health
states in the DALY methodology are restricted to “within
the skin” elements of functioning such as body func-
tions, senses, cognition, and ambulation. This restriction
is chosen in order to compare the relative magnitude of
decrements in health across diseases, countries, and time
[1,9,10]. “Out of skin” elements of functioning such as
participation restrictions, while important, are beyond
the scope of what the DALY aims to capture [10,11].
Within GBD methodology, the severity of each health
state is quantified using a disability weight. This allows
estimates of disease burden to capture differences in dis-
ability both between and within disorders [11,12]. In the
GBD 2010 Study, disability weights are being estimated
for around 230 health states [1,13] using two different
sources of data. A population-based survey has been
conducted in Bangladesh, Indonesia, Peru, Tanzania, and
the United States of America supplemented by an Inter-
net survey (gbdsurvey.org) to access as wide a range of
views as possible [12,13].
The purpose of this paper is to describe GBD health
states for schizophrenia and bipolar disorder. This
involves (1) presenting clinical definitions for each
health state and (2) using these definitions to quantify
the overall distribution of cases in each health state. Al-
though related, this is a separate exercise to the formula-
tion of lay descriptions of each health state included in
the population- and Internet-based disability weight sur-
veys mentioned earlier. Rather, the deliverables of this
paper will inform the differences within the course of
the disorder for which health state-specific disability
weights are being developed. The distribution of schizo-
phrenia and bipolar disorder cases across multiple health
states can be summarized differently depending on the
approach used. For instance, the number of cases within
the population in each state or the mean or median time
spent in each state may be reported. Since burden of dis-
ease estimates are cross-sectional measurements ofhealth loss in a population, in a particular year, the
former approach of measuring the number of cases in
each health state fits best and will be used here.
Methods
First a review of the literature was conducted to identify
health states to describe schizophrenia and bipolar dis-
order. This was followed by a systematic review to iden-
tify epidemiological data on the severity distribution
across health states. Finally, a meta-analysis was carried
out to pool the proportion of cases of schizophrenia and
bipolar disorder in each health state, across studies, for
use in burden estimation in the GBD 2010 Study.
Defining health states
Schizophrenia
There are a number of descriptions of schizophrenia in
the literature that could be used to describe the health
states found in this disorder. For GBD purposes health
state definitions were based on a diagnostic system and
general clinical experience, which converge on a small
set of descriptors. The two schizophrenia health states
for GBD are reminiscent of Crow’s [14,15] type I and
type II schizophrenia [16-18], which has influenced the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV-TR) [19].
The first health state, referred to as “acute”, was
ascribed to schizophrenia with predominantly positive
symptoms (e.g., delusions, hallucinations, and thought
disorder). The second health state, referred to as “re-
sidual”, was ascribed to schizophrenia with predomin-
antly negative symptoms (e.g., flat affect, loss of interest,
and emotional withdrawal). These health states are not
mutually exclusive. Positive symptoms can be followed
by the development of negative symptoms or they can
both occur simultaneously with one set of symptoms
being more noticeable than the other [14,19], and this
can be affected by treatment. Both positive and negative
symptoms are associated with impaired functioning [20].
Bipolar disorder
Both the DSM-IV-TR and the International Classifica-
tion of Diseases (ICD-10) describe bipolar disorder as
the experience of one or more manic (or hypomanic)
episodes and also one or more major depressive episodes
[19,21]. The health state categories selected were based
on this description. They were “manic”, “depressive”,
and “residual”. A manic state involves elevated, expan-
sive, or irritable mood. A depressive state involves
depressed mood or loss of interest in daily activities. A
residual state involves depressive or manic symptoms,
which are below the threshold for a manic or depressive
episode. A 20-year prospective study of bipolar I and II
disorders showed that there were significant variations in
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person was experiencing. Functioning was found to be
equally poor during manic and depressive states except
for a few instances when depression led to more disabil-
ity. In comparison, functioning significantly improved
when participants were less symptomatic (in a residual
state), although functioning in this state was still signifi-
cantly less than in controls [22].
Epidemiological data on health states
Two separate systematic literature reviews were con-
ducted to search for available epidemiological data on
these health states for schizophrenia and bipolar dis-
order. For each review, the methodology used was in line
with that proposed by the Meta-analysis Of Observa-
tional Studies in Epidemiology (MOOSE) Group [23].
Schizophrenia
For schizophrenia, relevant papers were accessed from
an existing database of a systematic review of the preva-
lence of schizophrenia covering studies published be-
tween 1965 and 2002 [24]. Studies included in the
analysis were those that reported the overall proportion
of individuals with schizophrenia experiencing acute and
residual states or provided sufficient data to calculate
the necessary proportions.
Bipolar disorder
For bipolar disorder, a systematic literature search was
conducted. A series of search strings were developed
and used to search electronic databases such as Medline
and PsycInfo. The literature search also involved review-
ing reference lists and contacting experts in the field to
obtain articles not identified through the database
search. Studies included in the present analysis were
those reporting the overall proportion of individuals
with a bipolar disorder experiencing manic, depressive,
and residual states or provided sufficient information to
calculate the necessary proportions. See Additional file 1
for further information on the literature search and
methodology.
Extracted data included information pertaining to the
study methodology and sample (e.g., study design, sample
ascertainment, location, age range) and the overall quality
of the study (e.g., methodological quality, sample repre-
sentativeness). Although current information (one month
or less) from the time of survey was the gold standard,
studies reporting longer ascertainment periods had to be
included to maximize inclusion. A quality index was used
to quantify the methodological quality of each study.
Quality was rated based on variables describing key areas
of the study methodology such as the ascertainment
period, the representativeness of the sample, and the
method of assessment. See Additional file 2 for moreinformation on the quality index. The difference in pro-
portions as a function of the economic status of the coun-
try from which the sample was drawn was also
investigated. Estimates were categorized according to
whether they were from developed, emerging, or develop-
ing economies, based on World Bank income categories
[25,26].
Analysis
MetaXL 1.0, a tool for meta-analysis in Microsoft Excel,
was used to pool health state proportions from each
study (see: http://www.epigear.com/). A “quality effects
model” was chosen over the more conventional fixed or
random effects models. This was to explicitly address
heterogeneity in pooled proportions [27]. The standard
in meta-analysis is to use the random effects model in-
stead of a fixed effects model in the presence of signifi-
cant heterogeneity. However, the random effects model
assumes that the observed heterogeneity is driven by real
differences in the distribution, when it is likely that it is
also caused by differences in study quality. MetaXL
implements a method to address study heterogeneity
caused by differences in study quality. This quality
effects model used quality scores from the systematic re-
view to weigh studies not only according to sample size
but also to study quality [28,29]. MetaXL ensures that
the pooled proportions add up to one.
Results
Schizophrenia
Of the 188 studies included in the original systematic re-
view for the prevalence of schizophrenia [24], only six
studies met the inclusion criteria for the present review
[30-35]. The three main reasons for exclusion were that
health state definitions were not consistent with how
they have been defined in this paper, that the data
reported were not in the format required for GBD, and
that only a subsample of the population was investigated
(e.g., high risk groups). Key features of the six included
studies are presented in Table 1.
Studies were drawn from five different countries
made up of three developing and emerging economies
[31,34,35] and two developed economies [30,32,33].
Given the limited number of studies, the study from an
emerging economy was combined with the two from
developing economies. Based on the combined six studies,
63% (38%-82%) of schizophrenia cases were in an acute
state and 37% (18%-62%) in a residual state (see Table 1).
Although the pooled proportion of cases in an acute state
was lower in the three developing/emerging countries
compared with the developed countries, this effect was
not statistically significant (54% (43%-65%) vs. 67% (46%-
82%)). Since there were only three studies in each group,
these estimates are indicative only, and more data would
Table 1 Summary of data from studies included for schizophrenia
Reference Country Age range
(years)
Number
of cases
Quality Index
Score (/1)
Percentage of
acute cases
Percentage of
residual cases
Bondestam et al., 1990 [31] Tanzania 15-99 10 0.7 60 40
Shen et al., 1981 [34] China 15-99 341 0.5 51 49
Zharikov, 1986 [35] Russia N/Sa 1429 0.3 50 50
Babigian, 1980 [30] USA 0-99 3319 0.5 62 38
Fichter et al., 1996 [32] Germany 18-99 7 0.8 75 25
Keith et al., 1991 [33] USA 18-99 305 0.9 69 31
Pooled health state proportions (%) (95% confidence intervals) 63%
(38%-82%)
37%
(18%-62%)
Note. Values rounded up to nearest whole number; aN/S: Not specified.
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whether a difference exists.
Bipolar disorder
Out of the 38 studies identified through the systematic
literature review, six studies met criteria for inclusion
[36-41]. The two main reasons for exclusion were that
health state definitions were not consistent with how
they have been defined in this paper and that the data
reported were not in the format required for GBD. Key
features of the six included studies are presented in
Table 2.
Five studies used samples from a different country
each [36,38-41] and one study used a sample from mul-
tiple European countries (Belgium, Denmark, Finland,
France, Germany, Greece, Ireland, Italy, Netherlands,
Norway, Portugal, Spain, Switzerland, and the United
Kingdom) [37]. Only one study provided estimates for a
developing economy (Ethiopia) [41] and reported 12% of
cases in a manic state and 13% in a depressive state.
Based on all six studies, 23% (10%-39%) of bipolar casesTable 2 Summary of data from studies included for bipolar d
Reference Country Age range
(years)
Number
of cases
Included
diagnosesa
Qua
Sc
Morgan et al.,
2005 [40]
Australia 18-64 112 BPI, BPII
Negash et al.,
2005 [41]
Ethiopia 15-49 295 BPI
Cruz et al.,
2008 [37]
Europeanb 18-92 1563 BPI
Faravelli
et al.,1990 [38]
Italy 15-99 6 BPI, BPII,
BPNOS
Have et al.,
2002 [39]
Netherlands 18-64 136 BPI, BPNOS
Blader et al.,
2007 [36]
USA 5-64 3900 BPI, BPII,
BPNOS
Pooled health states proportions (%) (95% confidence intervals)
Note. Values rounded up to nearest whole number; aBP: Bipolar; NOS: Not otherwis
Ireland, Italy, Netherlands, Norway, Portugal, Spain, Switzerland, and the United Kinwere in a manic state, 27% (11%-47%) were in a depres-
sive state, and 50% (30%-70%) were in a residual state
(see Table 2).
Discussion
The present review is a first attempt to systematically
pool data on schizophrenia and bipolar health states for
GBD. It revealed a lack of empirical data on the propor-
tion of cases in the different health states. Since the field
lacks readily operationalized criteria to describe schizo-
phrenia and bipolar disorder health states, the choice of
health states limited the data available. That said, defini-
tions selected were made as representative as possible
while remaining consistent to GBD methodology by
using internationally accepted diagnostic systems of
schizophrenia and bipolar disorder, which converge on a
small set of descriptors.
Our definition of health states for both disorders con-
formed as much as possible to ‘within the skin’ ele-
ments of functioning required by GBD. However, the
DSM diagnostic criteria and literature (particularly forisorders
lity Index
ore(/1)
Percentage of
manic cases
Percentage of
depressive cases
Percentage of
residual cases
1.0 19 20 62
0.9 12 13 75
0.9 11 11 79
0.8 33 50 17
0.9 41 28 32
0.6 28 37 35
23%
(10%-39%)
27%
(11%-47%)
50%
(30%-70%)
e specified; bEuropean: Belgium, Denmark, Finland, France, Germany, Greece,
gdom.
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tional impairment, part of which are dependent on the
environmental context. Consequently, trying to fit the
multidimensional features of schizophrenia into two
domains remains controversial. The fragility of the empir-
ical data is a concern, particularly the lack of consensus
on a health state definition and how the corresponding
proportion of cases in each state is measured. For the pur-
poses of this exercise, we have adopted a pragmatic
approach in using the best available data to come up
with a sensible set of health states (and health state
proportions) that can be used in the GBD 2010 Study.
More data on health states were available for bipolar
disorder than schizophrenia, which is likely to reflect
more agreement in the literature on the health states
that exist for bipolar disorder. Aside from estimating the
number of cases in each state, which was the format
used for GBD, some studies also estimated the time
spent in each state. As discussed previously, data in this
format were not included as they did not fit with GBD’s
cross-sectional approach to quantifying burden.
In support of the present findings, Judd and collabora-
tors’ 20-year prospective follow-up study investigating
the weekly polarity of symptoms in patients with bipolar
disorder showed that patients spent approximately three
times more follow-up weeks in a residual state compared
to a manic or depressive state [42]. This was also true in
studies conducted by Joffe and collaborators [43], Kupka
and collaborators [44], and Paykel and collaborators
[45]. Our finding of almost equal numbers of cases in
manic and depressive states, however, was not entirely
consistent with literature based on expert opinion, which
suggests that patients spend more time in a depressive
state than a manic state. Further investigation into the
alternative approaches to measuring the distribution of
schizophrenia and bipolar disorder health states in the
population and how these affect overall results (and ul-
timately burden estimates) is required for a better
understanding of the above findings.
Due to paucity in the literature, studies using clinical
samples were also included in this review. Although in-
patient samples may not be representative of the general
population, as most individuals will only be identified
for inclusion once their illness is sufficiently severe to re-
quire hospital admission [46,47], clinical samples com-
prising both in- and outpatient samples are likely to be
more representative where treatment rates are high. A
mixture of inpatient and broader clinical samples were
included in the present review. Studies included for bi-
polar disorder also differed in the subtype of bipolar dis-
order assessed. The study from Ethiopia [41] and the
one conducted across multiple European countries [37]
assessed bipolar I cases only, the latter of which also
included cases of bipolar I disorder with rapid cycling.Although this was less representative of the spectrum
of bipolar disorder, these studies were included to
maximize the global distribution of the data.
There were insufficient data to consider the impact of
treatment rates on the presentation of cases. It is
expected that treatment alters the proportion of cases in
each state. For instance, high treatment rates may lead
to less disability associated with an illness with more
cases in a residual state. Research in Western countries
has found that the prognosis for psychotic disorders
worsens with lack of treatment [48-50]. Evidence for this
in non-Western countries is not as clear. There has been
literature to suggest that patients with schizophrenia
have better functioning in developing countries where
treatment rates are low compared to in developed coun-
tries where it is high [51] and alternatively literature to
suggest that individuals with schizophrenia in developing
countries have significantly poorer prognosis than ori-
ginally thought [52].
Conclusions
Gaps in the literature meant that only a small selection
of studies could be used to derive pooled proportions.
Consequently, there may not have been enough data to
yield a representative indication of proportions. Also, the
data sources identified reported a range of methodo-
logical differences. This has led to considerable hetero-
geneity in the data. We expect that the inclusion criteria
used and the quality effects model has controlled for
some of this heterogeneity in the final pooled propor-
tions, but the wide uncertainty intervals reflect the poor
state of knowledge. Schizophrenia and bipolar disorder
both have a chronic course, with fluctuations in symp-
tomatology and disability [47,53,54]. Rather than deriv-
ing burden estimates that fail to capture the changes in
disability within these disorders, we will use the data
available to us to make more representative estimates of
disease burden in the GBD 2010 Study.
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